Portfolio analysis: Making Go/No-Go decisions to optimise the portfolio
When a pharma company is either considering acquiring a new agent, or developing one in-house, marketers need to understand the impact on the overall portfolio and decide whether to make a go or no-go decision on that asset.
Webcast: Rich in potential - Exploring the opportunity for nutritionals in emerging markets
A shift to preventative health has seen nutritionals emerge as a rapidly developing area in recent years. But while growth begins to level off in more established territories, attention is turning to emerging markets. Join Research Partnership's emerging market experts Paul Reed and Kira Pillai for our upcoming live webinar ‘Rich in potential: Exploring the opportunity for nutritionals in emerging markets’ in which they will explore the challenges and opportunities for the nutritionals sector in some of the world’s fastest growing markets.
Webcast: Portfolio tracking for success
Portfolio Analysis and Optimization looks at how honing strategy among multiple agents in the same therapeutic category leads to marketing success. As pharmaceutical companies simultaneously develop and in-license multiple products that can cost millions of dollars, portfolio management is about selecting how to allocate resources and marketing efforts across multiple assets. This has significant impact on the bottom line.
Live from Singapore: Going for growth - Maximising your return on insights in emerging markets
Healthcare market research in emerging markets is still evolving, so finding the insights you require and then maximising the return on those insights can be challenging. Download this complimentary webcast in which Emerging Markets experts Nicole Bender Moreira and Colin Tan will provide you with the critical success factors to ensure actionable primary research in emerging markets.
Webcast: Portfolio analysis - Choosing your communication strategy
Portfolio Analysis and Optimization concentrates on determining the impact that multiple assets within therapeutic categories, and the marketing of these assets, has on overall strategy. This is an important tool for pharmaceutical companies in today’s market. As they simultaneously develop multiple products that can cost millions of dollars, portfolio management to improve decision-making can have a significant impact on the bottom line. At its very core, it is about selecting how to allocate resources and marketing efforts across multiple assets.